Evidence map›Paper›PMID 30883503›Full record

ArticleTherapeutic drug monitoring2019

Ganciclovir Therapeutic Drug Monitoring: A Case Series.

Anne-Grete Märtson, Daan Touw, Kevin Damman, Martijn Bakker, Annemieke Oude Lansink-Hartgring, Tjip van der Werf, Marjolein Knoester, Jan-Willem C Alffenaar

Erratum issuedAbstract readCase Reports
In one paragraph

Article in Therapeutic drug monitoring, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Anne-Grete MärtsonDepartments of Clinical Pharmacy and Pharmacology.
Daan TouwDepartments of Clinical Pharmacy and Pharmacology.
Kevin DammanCardiology.
Martijn BakkerHematology.
Annemieke Oude Lansink-HartgringCritical Care.
Tjip van der WerfPulmonary Diseases and Tuberculosis.
Marjolein KnoesterMedical Microbiology and Infection Control, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Jan-Willem C AlffenaarDepartments of Clinical Pharmacy and Pharmacology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article presents 3 cases of immunocompromised patients for whom therapeutic drug monitoring of ganciclovir in combination with cytomegalovirus viral load measurement was used to guide treatment. The first patient is diagnosed with thymoma A, the second is a heart transplant recipient, and the third is an HIV-positive patient. These patients were all diagnosed with cytomegalovirus and treated with ganciclovir. Our case studies illustrate how therapeutic drug monitoring-guided dosing can be helpful in the management of these complex cases.

Indexed as

AdultAntiviral AgentsCytomegalovirus InfectionsDrug Administration ScheduleDrug MonitoringGanciclovirHumansImmunocompromised HostMaleMiddle AgedViral LoadAntiviral AgentsGanciclovir

Identifiers

PMID30883503
PMCPMC6426343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.